Esophageal cancer future or investigational therapies
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer future or investigational therapies |
|
FDA on Esophageal cancer future or investigational therapies |
|
CDC on Esophageal cancer future or investigational therapies |
|
Esophageal cancer future or investigational therapies in the news |
|
Blogs on Esophageal cancer future or investigational therapies |
|
Risk calculators and risk factors for Esophageal cancer future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Adavances in the treatment of esophageal cancer are focused on PET scanning for accurate staging and chemotherapeutics such ascapecitabine (Xeloda), cisplatin (Platinol), and docetaxel (Docefrez, Taxotere). Immunotherapy checkpoint inhibitors such as pembrolizumab (Keytruda) has shown some promising results.[1]
References
- ↑ Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009). "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria". Clin. Cancer Res. 15 (23): 7412–20. doi:10.1158/1078-0432.CCR-09-1624. PMID 19934295.